Agilent Technologies, a worldwide chief in analytical and laboratory options, in the present day introduced an growth of its collaboration with the Centre for Cellular and Molecular Platforms (C‑CAMP), a Department of Biotechnology supported initiative. The expanded engagement broadens access to superior analytical and mass spectrometry‑based mostly capabilities that assist life sciences and therapeutic analysis throughout India.
Through this collaboration, excessive‑decision analytical platforms will likely be made obtainable through C‑CAMP’s shared infrastructure, supporting purposes comparable to biotherapeutic characterization, oligonucleotide analysis, and quantitative biomolecular evaluation. The mannequin is designed to allow researchers from startups, academia and business to access superior analytical workflows and deep area experience with out the necessity for direct capital funding in specialised devices or amenities.
As India continues to strengthen its concentrate on translational analysis and the event of superior therapeutics, access to excessive‑high quality analytical infrastructure has grow to be more and more important. By increasing this collaboration, Agilent and C‑CAMP purpose to assist scale back entry boundaries and assist dependable, reproducible science throughout the analysis‑to‑improvement continuum.
Agilent’s collaboration with C‑CAMP has performed a catalytic position in advancing India’s biopharma ecosystem by enabling world‑class, regulatory‑aligned characterization of biologics and biosimilars throughout therapeutic purposes. Building on this momentum, the expanded collaboration deepens Agilent and C‑CAMP’s shared dedication to accelerating subsequent‑era biotherapeutics and reinforcing India’s ambition to emerge as a globally aggressive biopharma hub.
The engagement aligns with C‑CAMP’s imaginative and prescient in direction of constructing a linked ecosystem that helps science‑to‑impression pathways, whereas leveraging Agilent’s experience in analytical workflows and expertise enablement.
“India is a strategic priority for Agilent, and partnerships like this are central to how we expand access to critical scientific capabilities,” mentioned Nandakumar Kalathil, Country General Manager, Agilent India. “Working with C‑CAMP allows a broader community of researchers to leverage advanced analytical workflows that support high‑quality, reproducible science across discovery and translational research.”
“Across Asia Pacific, we are seeing a strong shift toward collaborative, shared infrastructure models that enable broader participation in advanced scientific research,” mentioned Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “Our expanded engagement
with C CAMP reflects Agilent’s commitment to building inclusive innovation ecosystems—where startups, academia, and industry can accelerate high quality research and translate science into meaningful impact.”
“Partnerships with frontier science and technology leaders such as Agilent will help C-CAMP build cutting-edge capabilities in India to support researchers and innovators across the country. In the coming years, we believe such collaborations will play a key role in enabling technology development and accelerating science-led innovation,” mentioned Dr Taslimarif Saiyed, Director and CEO, C‑CAMP. “The engagement also aligns with C-CAMP’s vision of building a connected ecosystem that supports science-to-impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.”
The expanded collaboration displays Agilent’s continued dedication to supporting India’s life sciences panorama by enabling scalable access to superior analytical capabilities by means of trusted shared platforms.